Podcasts

Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA.

In this episode, they discuss three papers: the impact of TOF treatment on weight and BMI in RA patients, to that of alternate treatment options for RA patients with prior MTX-inadequate response, and the treatment of JAKis versus TNFis in RA.

Podcast: AuToDeCRA, June 2025

Join Professor Ian McInnes from the University of Glasgow, and Professors John Isaacs and Andrew Cope, as they discuss the latest AuToDeCRA study and what this means for rheumatology.

Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA.

In this episode, he discusses two papers: risk of MACE in patients with RA treated with JAKis compared to bDMARDs from the “JAK-pot” study, and the efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with RA and an inadequate response to MTX.

Discussing PsA: Real-world data on biologic switching and the development of EMMs

Join Professors Philip Mease and Laura Coates and as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on biologic switching for the treatment of PsA using real-world data as well as the development of extramusculoskeletal manifestations in PsA and axSpA patients treated with upadacitinib.

Webinar Highlights Podcast: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs

Join Professors Herve Bachelez and Tim Orchard as they discuss the recent webinar hosted on the IMID Forum: “Advancing Patient Care Through an Interdisciplinary Approach to IMIDs." Watch them discuss key highlights from the webinar, including the clinical pathogenetic pathways, the Rheum-Derm-Gastro triggers and their implications, and interdisciplinary management in IBD and psoriasis.

Author Interview: Dr Saqr Alsakarneh, May 2025

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Saqr Alsakarneh, Internal Medicine Resident at University of Missouri–Kansas City in the US, as they discuss ‘Risk of De Novo Inflammatory Bowel Disease in Patients with Psoriasis and Psoriatic Arthritis Treated with IL-17A Inhibitors: A Population-Based Study’.